Loading…
Arcturus Therapeutics Holdings Inc. is projected to rise to $7.55 by 2027, a +8% move from its current price of $6.97. ARCT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $6.79 | $6.97 | $7.16 | +0.05% |
| Jul 15 | $6.72 | $6.98 | $7.25 | +0.10% |
| Jul 16 | $6.66 | $6.98 | $7.31 | +0.15% |
| Jul 17 | $6.62 | $6.98 | $7.37 | +0.19% |
| Jul 18 | $6.58 | $6.99 | $7.42 | +0.24% |
| Jul 19 | $6.54 | $6.99 | $7.47 | +0.29% |
| Jul 20 | $6.51 | $6.99 | $7.51 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.51 | $6.99 | $7.51 | +0.34% |
| Week 2 | $6.35 | $7.02 | $7.76 | +0.68% |
| Week 3 | $6.22 | $7.04 | $7.97 | +1.02% |
| Week 4 | $6.13 | $7.06 | $8.15 | +1.36% |
| Week 5 | $6.05 | $7.09 | $8.31 | +1.71% |
| Week 6 | $5.97 | $7.11 | $8.47 | +2.05% |
| Week 7 | $5.91 | $7.14 | $8.62 | +2.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency.
In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
ARCT is currently priced at $7.16, reflecting its current market position in the healthcare sector. The stock carries a market capitalization of $203.51M and is ranked 3816 by market cap/size among traded assets.
The forecast outlook presents a year-by-year path with the 2026 average price at $7.16 and a bullish trajectory extending through 2050, with the maximum forecast price hitting $66.49 and the minimum at $7.82 in 2030. The implied return on investment (ROI) progresses from 0 in 2026 to 402.9 in 2050, with sentiment improving to BULLISH in the later years.
A major floor 15.0% below — a decisive break under it would weaken the trend.
The nearest floor, 3.6% below — buyers have tended to step in here.
The nearest ceiling, 15.4% above — a clean break opens room to run.
A major ceiling 32.3% above — clearing it would confirm fresh momentum.
Key ARCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.28 | Sell | $7.15 | Sell |
| MA 10 | $7.10 | Sell | $7.15 | Sell |
| MA 20 | $7.12 | Sell | $7.19 | Sell |
| MA 50 | $7.55 | Sell | $7.42 | Sell |
| MA 100 | $7.67 | Sell | $7.80 | Sell |
| MA 200 | $8.98 | Sell | $9.12 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.58 | Neutral |
| Stoch RSI (14) | 33.39 | Neutral |
| CCI (20) | -48.35 | Neutral |
| Williams %R (14) | -71.59 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -1.55 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 28.41 | Neutral |
| TRIX (15) | -0.27 | Sell |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 50.21 | Neutral |
| Momentum (10) | 0.15 | Buy |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 7.29 | Sell |
| ADX (14) | 11.87 | Neutral |
| ATR (14) | 0.20 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 50. SMA50 is $7.59 and SMA200 is $9.05, framing a modest near-term landscape. The stock sits above a support level of $6.72 and below a resistance at $8.04, suggesting a contained trading range.
Over the last 30 days, the price has traded within a low of $5.98 and a high of $8.57, highlighting a relatively tight range with potential for moves toward the defined support or resistance levels. Annualized volatility sits around 50% as a measure of price variability over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.25 | $6.97 | $9.02 | 0% | Neutral | |
| $6.02 | $7.55 | $10.01 | +8% | Neutral | |
| $7.21 | $9.30 | $12.79 | +33% | Bullish | |
| $8.13 | $10.72 | $15.18 | +54% | Bullish | |
| $7.48 | $10.06 | $14.59 | +44% | Bullish | |
| $7.66 | $10.50 | $15.55 | +51% | Bullish | |
| $8.14 | $11.35 | $17.13 | +63% | Bullish | |
| $8.13 | $11.52 | $17.69 | +65% | Bullish | |
| $9.95 | $14.30 | $22.30 | +105% | Bullish | |
| $10.60 | $15.47 | $24.47 | +122% | Bullish | |
| $13.98 | $21.79 | $36.64 | +213% | Bullish | |
| $19.18 | $33.45 | $61.50 | +380% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $6.25 | $6.97 | $8.52 | +0.00% |
| August 2026 | $6.28 | $7.41 | $8.97 | +6.27% |
| September 2026 | $6.13 | $7.28 | $8.92 | -1.66% |
| October 2026 | $5.96 | $7.12 | $8.80 | -2.26% |
| November 2026 | $6.02 | $7.23 | $9.00 | +1.50% |
| December 2026 | $5.96 | $7.19 | $9.02 | -0.49% |
Click any year to see its month-by-month ARCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ARCT price prediction for 2026 points to an average of $6.97 (low $6.25, high $9.02) — a potential gain of 0% on today's $6.97. A consolidation phase looks the most probable path here.
In 2027, ARCT is projected to trade between $6.02 and $10.01, averaging $7.55 — a potential gain of +8% from today's $6.97. That is up +8% on the projected 2026 average. Price action looks broadly range-bound.
Arcturus Therapeutics Holdings Inc.'s 2028 outlook centres on $9.30, within a $7.21 to $12.79 range. That is up +23% on the projected 2027 average. That marks a +33% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ARCT could reach as high as $15.18, with a base case around $10.72 and support toward $8.13 — roughly +54% from $6.97. Momentum favours further upside here.
Expect ARCT to range from $7.48 to $14.59 through 2030. The $10.06 average target implies a +44% move from current prices. That is -6% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
The ARCT price prediction for 2031 points to an average of $10.50 (low $7.66, high $15.55) — a potential gain of +51% on today's $6.97. Momentum favours further upside here.
In 2032, ARCT is projected to trade between $8.14 and $17.13, averaging $11.35 — a potential gain of +63% from today's $6.97. That is up +8% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Arcturus Therapeutics Holdings Inc.'s 2033 outlook centres on $11.52, within a $8.13 to $17.69 range. That is up +1% on the projected 2032 average. That marks a +65% change versus current levels. Momentum favours further upside here.
By 2034, ARCT could reach as high as $22.30, with a base case around $14.30 and support toward $9.95 — roughly +105% from $6.97. Buyers look set to stay in control over this stretch.
Expect ARCT to range from $10.60 to $24.47 through 2035. The $15.47 average target implies a +122% move from current prices. That is up +8% on the projected 2034 average. Momentum favours further upside here.
The ARCT price prediction for 2040 points to an average of $21.79 (low $13.98, high $36.64) — a potential gain of +213% on today's $6.97. Buyers look set to stay in control over this stretch.
In 2050, ARCT is projected to trade between $19.18 and $61.50, averaging $33.45 — a potential gain of +380% from today's $6.97. That is up +54% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ARCT today (≈ 143.472023 ARCT) could be worth
$4,799.78
+$3,799.78 (+380%) by 2050 · US Dollar
Based on the average projected ARCT price of $33.45 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARCTwould be worth at today's price.
$1,000 invested in ARCT on Jul 10, 2025 (≈ 69.060776 ARCT) would be worth
$481.35
-$518.65 (-51.9%) today · 0.48× · US Dollar
Based on a ARCT entry price of $14.48 vs. today's $6.97.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.28 | $957.42 | -4.3% |
| 1 month ago | $6.89 | $1,011.61 | +1.2% |
| 3 months ago | $8.36 | $833.73 | -16.6% |
| 6 months ago | $7.53 | $925.63 | -7.4% |
| 1 year ago | $14.48 | $481.35 | -51.9% |
| All time (5.0y) ago | $27.88 | $250 | -75.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARCT forecast.
Our base-case forecast reaches $14.00 around 2034.
Implied market cap at $14.00: $397.92M
The multi-year forecast paints a bullish pathway with meaningful upside in the coming years. The 2026 forecast shows a min of $6.25, an avg of $7.16, and a max of $9.29 with a neutral sentiment, setting the baseline for later growth.
From 2027 onward, the outlook turns more constructive. The 2027 avg is $7.86 (ROI 9.8) and 2028 is $9.75 (ROI 36.2), followed by 2029 at $11.21 (ROI 56.6) and 2030 at $10.54 (ROI 47.2). The sequence continues with 2031 at $11.06 (ROI 54.5), 2032 at $11.98 (ROI 67.3), and 2033 at $12.24 (ROI 70.9).
2034 is projected to rise to an avg of $15.26 (ROI 113.2) and 2035 to $16.45 (ROI 129.8), illustrating a strengthening longer-term trend that feeds into the later years.
By 2040, the avg is $23.50 with a max of $39.68 (ROI 228.2) and sentiment bullish, and by 2050 the avg reaches $36.00 with a max of $66.49 (ROI 402.9) holding a bullish stance throughout the horizon. These numbers are estimates and not guarantees; actual results depend on numerous factors across the health-care and biotech landscape.
Tap a question to reveal the answer.
In 2030, the forecast shows a 2026–2030 path with an avg price of $10.54, a min of $7.82, and a max of $15.32, with ROI 47.2 and a BULLISH sentiment.
The forecast depicts a transition from NEUTRAL in 2026 to BULLISH in later years, with the avg price rising to $36.00 by 2050 and ROI 402.9. These are estimates, not guarantees.
The forecast shows higher-price milestones including a 2034 max of $23.87, a 2040 max of $39.68, and a 2050 max of $66.49, indicating that reaching $20 is plausible within the projection.
Current price is $7.16 and market cap is $203.51M.
The 30-day range is $5.98 to $8.57. RSI is 50; SMA50 is $7.59; SMA200 is $9.05. Support is at $6.72 and resistance at $8.04, with annualized volatility at 50%.
Arcturus Therapeutics Holdings Inc. Community Discussion
0Share your Arcturus Therapeutics Holdings Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.